The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 62 , ISSUE 2 ( April-June, 2020 ) > List of Articles

EDITORIAL

Management of Chronic Respiratory Diseases in the Era of COVID-19

D. Behera

Citation Information : Behera D. Management of Chronic Respiratory Diseases in the Era of COVID-19. Indian J Chest Dis Allied Sci 2020; 62 (2):45-50.

DOI: 10.5005/ijcdas-62-2-45

License: CC BY-NC 4.0

Published Online: 07-11-2022

Copyright Statement:  Copyright © 2020; The Author(s).


Abstract

PDF Share
  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
  2. WHO. Coronavirus disease (COVID-19) Pandemic. 2020. Available from URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2919. Accessed on June 10, 2020.
  3. Covid-19 dash board by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from URL: Accessed on July 1, 2020.
  4. Noncommunicable Diseases Country Profiles 2018. Geneva: World Health Organization, 2018, 223. Available from URL: https://www.who.int/nmh/publications/ncd-profiles-2018/en. Accessed on June 10, 2020:
  5. Khaltaev N, Axelrod S. Chronic respiratory diseases global mortality trends, treatment guidelines, life style modifications, and air pollution: preliminary analysis. J Thorac Dis 2019;11:2643–55.
  6. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980- 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–88.
  7. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858.
  8. Arokiasamy P. India's escalating burden of non-communicable diseases. Lancet Glob Health 2018;6:e1262–e1263.
  9. India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6:e1363–e1374.
  10. Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Global Health 2019;7:e1269-e1279.
  11. Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012;16:1270–7.
  12. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 2015;32:138–46.
  13. Singh V, Sharma BB. Respiratory disease burden in India: Indian Chest Society SWORD survey. Lung India 2018;35:459–60.
  14. Singla N, Singla R, Fernandes S, Behera D. Post treatment sequelae of multi-drug resistant tuberculosis patients. Indian J Tuberc 2009;56:206–12.
  15. Gandhi K, Gupta S, Singla R. Risk factors associated with post-TB sequele. Indian J Tuberc 2016;63:34–38.
  16. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology Eur Respir Rev 2018;27:170077.
  17. Singla R, Mallick M, Mrigpuri P, Singla N, Gupta A. Sequelae of MDR-TB at treatment completion. Lung India 2018;35:4–8.
  18. Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, et al. Interstitial lung disease in India: results of a Prospective Registry. Am J Respir Crit Care Med 2017;195:801–13.
  19. Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, et al. Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS One 2018;13:e0191938.
  20. Kumar R, Gupta N, Goel N. Spectrum of interstitial lung disease at a tertiary care centre in India. Pneumonol Alergol Pol 2014;82:218–226.
  21. Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One 2014;9:e114745.
  22. Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults > /=60 years old. Open Forum Infect Dis 2018;5:ofy316.
  23. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167–73.
  24. Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC, et al. Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev 2019;28:180063.
  25. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011;183:734–42.
  26. Wark PA, Tooze M, Powell H, Parsons K. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology 2013;18:996–1002.
  27. Khaltaev N. GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. J Thorac Dis 2017;9: 4676–89.
  28. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a Nationwide analysis. Eur Respir J 2020;55:2000547.
  29. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8:436–8.
  30. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.
  31. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
  32. Lippi G, MichaelHenry B. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 2020;167:105941
  33. Halpin DMG, Faner R, Sibila O, Badia JR. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020;8:436–38.
  34. Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID Guidance. 2020.
  35. Global Initiative for Asthma. COVID-19: GINA answers to frequently asked questions on asthma management. 2020.
  36. To T, Viegi G, Cruz AA. Taborda-Barata L, Asher I, Behera D, et al. A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J 2020 (Accepted, under publication).
  37. World Health Organization. COVID-19 Global Overview.
  38. Available from URL: https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html. Accessed on April 19, 2020).
  39. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intens Care Med 2020;46:854–87.
  40. Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. JAMA 2020;323:839–41.
  41. Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff BD, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med 2020;201:1560–64.
  42. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med 2020;9:428–36.
  43. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213–7.
  44. Myllyvirta L, Dahiya S. Air quality improvements due to COVID 19 lock-down in India assessment of NO2 satellite data from Sentinel 5P-TROPOMI for period of 11th March –24th March and 25th March –7th April for 2019 and 2020. Center For Research on Energy and Clean Air (CREA). 2020.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.